Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Two Experts Discuss HIV, Abdominal Fat and Body Shape Changes

Watch TheBody.com's HIV and Aging Expert Nelson Vergel interview Dr. Stephen Grinspoon, Professor at Harvard Medical School and the Director of a Program in Nutritional Metabolism at Massachusetts General Hospital about the causes of body shape changes in HIV -- and most importantly, what you can do about them.

Published
24 August 2016
From
The Body
Efavirenz appears to be associated with elevated suicide risk in START trial

Participants in the START treatment-timing trial who took antiretroviral regimens containing efavirenz had an increased risk of suicidal and self-injuring behaviour than those not using efavirenz, though

Published
10 August 2016
By
Liz Highleyman
Gilead defeats AIDS activists who claimed the company manipulated patents

Gilead Sciences won a victory last week when a federal court judge tossed a lawsuit in which an AIDS activist group accused the drug maker of manipulating the patent system in order to thwart competition for its HIV medicines. At issue was tenofovir, or TDF, which Gilead is replacing with a modified version known as TAF.

Published
13 July 2016
From
STAT
Switching from tenofovir DF to TAF improves bone and kidney safety

People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements

Published
11 July 2016
By
Liz Highleyman
Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis

Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.

Published
02 June 2016
From
New York Times
A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.

Published
30 May 2016
From
Los Angeles Times
Rare but severe liver side-effects reported among South African patients starting efavirenz-based ART

Treatment with efavirenz has been associated with rare but severe liver complications among patients receiving antiretroviral therapy (ART) in South Africa. Writing in AIDS, investigators report three patterns

Published
27 May 2016
By
Michael Carter
In Option B+, side-effects and needing time to think are key reasons for not taking HIV medication

A qualitative study of women in Malawi who chose not to take HIV treatment as part of the country’s Option B+ programme, or who interrupted their treatment,

Published
19 May 2016
By
Roger Pebody
START study shows that people starting HIV treatment earlier have better quality of life

Rather than treatment side-effects having a negative impact on people’s quality of life when they start HIV treatment, data from the large randomised START study show a

Published
07 March 2016
By
Roger Pebody
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC, Emtriva), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched

Published
25 February 2016
By
Liz Highleyman
← First12345...75Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close